tbuckley/cabot-search huggingface dataset:
Identification of Na+/I- symporter phosphorylation sites and their biological significance
Authors: Douangsone Vadysirisack, Zhaoxia Zhang, Ming-Daw Tsai, Sissy Jhiang
Journal: Cancer Research (2007)

LB-307  The Na+/I- symporter (NIS) mediated iodide uptake activity is the basis for targeted radioiodide ablation of thyroid cancers. While it has been shown that NIS protein is phosphorylated, no NIS phosphorylation site in vivo has been reported. To identify NIS phosphorylation sites, we conducted proteomic analysis of NIS immunoprecipitates from Flag-tagged rat NIS transfected HEK 293 cells. We identified S43, T49, S227, T315, T575 or T577, and S581 as in vivo NIS phosphorylation sites by mass spectrometry. To characterize the functional significance of these NIS phosphorylation sites, we generated Flag-tagged rat NIS mutants with single phospho-defective or phospho-mimicking mutations and evaluated NIS-mediated radioiodide uptake (RAIU) activity, total NIS protein levels, as well as cell surface NIS levels in transfected HEK 293 cells. Our study indicates that (1) the phosphorylation status of S43 and S581 appears to modulate NIS activity without affecting cell surface NIS levels or total NIS protein levels; (2) the phosphorylation status of T577 may be important for NIS protein stability, as NIS phospho-defective mutant T577A had decreased total protein levels while NIS phospho-mimicking mutant T577D had comparable total protein levels as wildtype NIS; and (3) the threonine residue at position 49 of NIS may be critical for proper local structure/conformation of NIS protein since mutation of T49 to either alanine or aspartic acid both resulted in reduced RAIU activity, without alterations in total or cell surface NIS protein levels.
Magnetic nanoparticles coated with polyphenols for spatio-temporally controlled cancer photothermal/immunotherapy
Authors: Fan Zhang, Guihong Lu, Xiaolei Wen, Feng Li, Xiaoyuan Ji, Qianqian Li, Meiying Wu, Qinzhen Cheng, Yongkang Yu, Jing Tang, Lin Mei
Journal: Journal of Controlled Release (2020)
Sox2 expression in brain tumors: a reflection of the neuroglial differentiation pathway
Authors: Ji Hoon Phi, Seung-Ki Kim, Chae-Yong Kim, Sung-Hye Park, Jin Hyun Kim, Yun Jin Lee, Sun Ha Paek, Chul-Kee Park, Byung-Kyu Cho, Kyu-Chang Wang
Journal: Cancer Research (2008)

2189  Sox2 is a key transcription factor that maintains the proliferation of neuroglial stem cells and inhibits neuronal fate commitment. Moreover, it was recently found that brain tumors contain stem cells that resemble normal neuroglial stem cells in many respects. This study was undertaken to describe Sox2 expression in various brain tumors, and to determine whether Sox2 expression is a universal feature of brain tumors, or whether its expression is limited to a specific lineage of brain tumors.  Sox2 immunohistochemistry was performed on 194 brain tumor tissues of various kinds. Fetal and adult normal brain tissues obtained by autopsy and brain tissues of epilepsy patients with cortical dysplasia were used as controls. Reverse transcription polymerase chain reaction was used to confirm the immunohistochemical results. Double immunofluorescence was performed to characterize the lineage of Sox2-positive cells.  Sox2 was found to be expressed in various glial tumors, including those with astroglial, oligodendroglial, and ependymal lineages, and in the glial components of mixed neuroglial tumors, regardless of pathological grade. In brain tumors of embryonal origin, supratentorial primitive neuroectodermal tumors showed robust Sox2 expression, whereas medulloblastomas and pineoblastomas did not. The majority of Sox2-positive tumor cells co-expressed glial fibrillary acidic protein, and most Sox2-negative cells in medulloblastomas and pineoblastomas showed neuronal differentiation.  This study suggest that Sox2 may be a tumor marker of glial lineages rather than a universal brain tumor stem cell marker, because its expression pattern was found to correspond to differentiation pathways. On the other hand, the aberrant co-expressions of Sox2 and of a neuronal marker were widely observed in glioblastomas, which reflects a disorganized differentiation pattern that characterizes highly malignant tumors.
Inflammatory bowel disease is associated with higher dementia risk: a nationwide longitudinal study
Authors: Bing Zhang, Hohui E Wang, Ya-Mei Bai, Shih-Jen Tsai, Tung-Ping Su, Tzeng-Ji Chen, Yen-Po Wang, Mu-Hong Chen
Journal: Gut (2020)

Increasing evidence supports reciprocal communication between the enteric and the central nervous system in disease, termed the 'gut-brain axis'. Recent findings suggest a connection between IBD and development of Parkinson's disease. The role of IBD in dementia, another insidious neurodegenerative disorder, has not been explored.
FRI0602-HPR PERSISTENT HYPOCOMPLEMENTEMIA IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Authors: M. L. Leguizamón, Y. Soria Curi, S. M. Mazza, G. V. Espasa, F. J. Hüttmann, H. R. Sueldo, A. L. Barbaglia, M. C. Bertolaccini, L. Gonzalez Lucero, P. R. Maldonado, M. Santana, L. M. Galindo, V. I. Bellomio
Journal: Annals of the Rheumatic Diseases (2020)

Background: Systemic lupus erythematosus (SLE) is a systemic, chronic, autoimmune disease of unknown cause characterized by a wide variety of clinical manifestations and autoantibody production. The complement is useful in the initial diagnosis, as an activity marker and for the follow-up of patients with SLE. Individual components may fluctuate only slightly with disease activity and C4 may even remain low during remission. Hypocomplementemia is associated with renal involvement, cutaneous vasculitis, diffuse alveolar hemorrhage, however, patients with persistent hypocomplementemia are not characterized yet. Objectives: 1) Determine the prevalence of persistent hypocomplementemia in patients with SLE. 2) Identify clinical characteristics, disease activity and accumulated damage in these patients. Methods: A longitudinal study was conducted with a review of the medical records of patients diagnosed with SLE (ACR criteria 82/97) who attended the Rheumatology Service between January 2000 and December 2015. Patients with a minimum evolution time of 6 months from the diagnosis of SLE with quarterly controls and monitoring for 2 years. Persistent Hypocomplementemia (PHC) was defined at C3 and / or C4 values below the normal range of the reference laboratory in a sustained form for at least 24 months. Demographic variables, clinical manifestations, disease activity by SLEDAI 2k, flare by SELENA SLEDAI and accumulated damage by SLICC / SDI were analyzed. Results: Clinical records of 254 patients with SLE were reviewed and 144 were included; 96% were women, with a mean age at diagnosis of SLE of 30.5 ± 11.2 years and a time of evolution of the disease at the last control 11.85 ± 7.8 years. Forty-one patients had PHC (28.5%; 95% CI 21.1, 35.8). The median of evolution time disease at the moment of PHC was 1 year (0-24) and the mean time of persistence of hypocomplementemia was 56 ± 46 months. In the univariate analysis, PHC was associated with hematological involvement during the course of the disease (p=0.01). Patients with PHC had a higher frequency of severe flare during follow-up (p=0.02). PHC was not associated with age of onset of SLE, disease activity (maximum SLEDAI reached), accumulated damage or death. Applying Logistic Regression Model with dependent variables with a level of significance &lt;0.25, PHC was associated independently with hematological compromise (OR 3.2). Conclusion: In this cohort of patients, the prevalence of PHC was 28.5%. PHC was associated with severe flare and hematological compromise. Disclosure of Interests: None declared
3-Dimensional CT Planning for Cerebral Embolic Protection in Structural Interventions
Authors: Guson Kang, James Lee, Thomas Song, Milan Pantelic, Nicholas Reeser, Thomas Keimig, Jeffrey Nadig, Pedro Villablanca, Tiberio Frisoli, Marvin Eng, William W. O’Neill, Dee Dee Wang
Journal: JACC. Cardiovascular imaging (2020)
Rashford, racism, and bankrupt excuses
Authors: Kamran Abbasi
Journal: BMJ (2020)

In a week when rioting protesters gave “football lads” a bad name, a lad who merely plays football for Manchester United showed that our priorities should be focused on protecting the nation’s vulnerable children. Marcus Rashford grew up relying on free school meals. He reached beyond politics to a common humanity, but his appeal to the UK government to extend its current scheme through the school holidays was at first dismissed.

Rashford has science on his side. Ian Sinha and colleagues include the rising tide of food insecurity in their list of ways in which children’s health and wellbeing are being sidelined by covid-19.1 The long term …
Are all distances created equal? Insights from developmental psychology
Authors: Bronwyn O'Brien, Joshua L. Rutt, Cristina M. Atance
Journal: Behavioral and Brain Sciences (2020)

Abstract Gilead et al.'s theory presupposes that traversing temporal, spatial, social, and hypothetical distances are largely interchangeable acts of mental travel that co-occur in human ontogeny. Yet, this claim is at odds with recent developmental data suggesting that children's reasoning is differentially affected by the dimension which they must traverse, and that different representational abilities underlie travel across different dimensions.
Covid-19: Government must plan for schools to reopen, say paediatricians
Authors: Abi Rimmer
Journal: BMJ (2020)

Over 1500 paediatricians in the UK have called on the prime minister to publish a clear plan for getting children back to school.

In an open letter to Boris Johnson, signed by1633 paediatricians, the Royal College of Paediatrics and Child Health (RCPCH) called on the UK government and the Northern Ireland Executive to publish clear plans for getting children back to school.

It also called on all UK governments to deliver recovery plans …
Author Correction: A large-scale test of the link between intergroup contact and support for social change
Authors: Tabea Hässler, Johannes Ullrich, Michelle Bernardino, Nurit Shnabel, Colette Van Laar, Daniel Valdenegro, Simone Sebben, Linda R. Tropp, Emilio Paolo Visintin, Roberto González, Ruth K. Ditlmann, Dominic Abrams, Hema Preya Selvanathan, Marija Brankovic, Stephen Wright, Jorina von Zimmermann, Michael Pasek, Anna Lisa Aydin, Iris Žeželj, Adrienne Pereira, Nóra Anna Lantos, Mario Sainz, Andreas Glenz, Hana Oberpfalzerová, Michal Bilewicz, Anna Kende, Olga Kuzawinska, Sabine Otten, Edona Maloku, Masi Noor, Pelin Gul, Jessica Pistella, Roberto Baiocco, Margareta Jelic, Evgeny Osin, Orly Bareket, Dinka Corkalo Biruski, Jonathan E. Cook, Maneeza Dawood, Lisa Droogendyk, Angélica Herrera Loyo, Kaltrina Kelmendi, Luiza Mugnol Ugarte
Journal: Nature Human Behaviour (2020)
Abstract IA08: Use of liquid biopsy to facilitate drug development in early-stage disease—FDA perspective
Authors: Julia A. Beaver
Journal: Clinical Cancer Research (2020)

Abstract Background: With advances in precision oncology, liquid biopsies have shown promise as a minimally invasive means to potentially diagnose cancer, detect resistance mutations and monitor tumor evolution, predict relapse, provide prognosis, and guide treatment decisions. One unique setting for the use of liquid biopsy to facilitate drug development is in early-stage disease where there is the potential for use in patient selection, prognostication, and drug activity demonstration. Discussion: From the regulatory and clinical trial perspective, liquid biopsies can be used as prognostic biomarkers to identify the likelihood of disease recurrence in early-stage cancer. For example, circulating cell-free tumor DNA (ctDNA) in an adjuvant cancer setting affords the potential to select a high-risk population that could be utilized as a stratification factor, or selection of an enriched high-risk population in which specific drug development could be pursued. Use of liquid biopsy as a putative surrogate endpoint or efficacy-response biomarker, in this setting, would require a large body of evidence demonstrating biologic plausibility, demonstration of studies of prognostic value of the surrogate endpoint for the clinical outcome, and evidence from clinical trials (or meta-analysis) that the treatment effects on the biomarker correlate to the long-term outcome. Another use of liquid biopsy as an efficacy-response biomarker could allow for go or no-go decision making earlier on in drug development, which could also be applied in the adjuvant setting. Conclusions: Liquid biopsies will continue to play a role in the clinical management of malignancies and have the potential to support drug approval and become more broadly incorporated and utilized in early-stage clinical trials. Citation Format: Julia A. Beaver. Use of liquid biopsy to facilitate drug development in early-stage disease—FDA perspective [abstract]. In: Proceedings of the AACR Special Conference on Advances in Liquid Biopsies; Jan 13-16, 2020; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(11_Suppl):Abstract nr IA08.
Vegetable Consumption and Progression of Prostate Cancer
Authors: Conor P. Kerley
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract B59: Validation of an exosomal osteosarcoma-associated gene signature in dogs with osteosarcoma
Authors: Kelly M. Makielski, Alicia J. Donnelly, Milcah C. Scott, Hirotaka Tomiyasu, Ali Khammanivong, William C. Kisseberth, Jaime F. Modiano
Journal: Clinical Cancer Research (2020)

Abstract Introduction: Osteosarcoma, the most common primary bone tumor in dogs, has a guarded prognosis. A major hurdle in developing more effective therapies is the lack of osteosarcoma-specific biomarkers to predict risk, prognosis, or therapeutic response. Exosomes are secreted microvesicles emerging as powerful diagnostic tools. However, wide clinical use of exosomes is precluded by the difficulty in identifying diseased cargo from the vastly larger background of normal cargo. We developed a method to distinguish tumor-derived exosome cargo from normal background, allowing for identification of an osteosarcoma-specific gene signature. Methods: Serum exosomes were enriched from osteosarcoma xenografts and control mice. Enriched genes associated with canine osteosarcoma were identified with RNA-sequencing. From identified candidates, we defined an osteosarcoma-associated gene signature. qRT-PCR amplification validated the gene signature in serum exosomes from clinical canine cases. Machine learning algorithms classified patients into disease groups based on this gene signature. Results: We identified an osteosarcoma-associated signature consisting of five mRNAs (SKA2, NEU1, PAF1, PSMG2, and NOB1). Serum exosomes were isolated from dogs in clinical groups, including “healthy,” “osteosarcoma,” “other bone tumor,” or “non-neoplastic disease.” Machine learning classified samples, with 82% and 86% of untrained samples predicted as osteosarcoma by CN2 and RF models, respectively. Post-treatment samples “misclassified” as non-osteosarcoma were associated with longer remissions, potentially from a lack of remaining osteosarcoma cells. Conclusions: We identified a gene signature associated with canine osteosarcoma. This gene signature was validated by qRT-PCR with serum exosomes from patients with osteosarcoma, as well as used to train artificial intelligence to correctly classify canine patients according to disease group with up to 93.8% accuracy. Clinical Significance: This study combines a bioinformatics approach to biomarker discovery with machine learning to correctly identify osteosarcoma in canine patients. These results set the stage for future discoveries to inform cancer risk, diagnosis, prognosis, and response to therapy. Citation Format: Kelly M. Makielski, Alicia J. Donnelly, Milcah C. Scott, Hirotaka Tomiyasu, Ali Khammanivong, William C. Kisseberth, Jaime F. Modiano. Validation of an exosomal osteosarcoma-associated gene signature in dogs with osteosarcoma [abstract]. In: Proceedings of the AACR Special Conference on Advances in Liquid Biopsies; Jan 13-16, 2020; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(11_Suppl):Abstract nr B59.
Abstract 19273: Impact of Sheath-Femoral Artery Diameter Ratio on Predicting Vascular Complications in Femoral Transcatheter Aortic Valve Implantation
Authors: Kentaro Hayashida, Thierry Lefévre, Bernard Chevalier, jhonathan Uribe, Mauro Romano, Thomas Hovasse, Philippe Garot, Marie-Claude Morice
Journal: Circulation (2010)

Purpose: To elucidate risk factors (RF) which predict vascular complication of percutaneous femoral artery (FA) closure for transcatheter aortic valve implantation (TAVI). Method: Eighty-five conse...
Clinical significance of transforming growth factor beta-1, monocyte chemoattractant protein-1, soluble type fractalkine and hialuronic acid in patients with chronic pancreatitis and pancreatic adenocarcinoma
Authors: A. Gąsiorowska, R. Talar-Wojnarowska, Anna Borkowska, Leszek Czupryniak, E. Małecka-Panas
Journal: Gut (2011)
Deletion of Glutathione S-Transferase Omega 1 Activates Type I Interferon Genes and Downregulates Tissue Factor
Authors: Yibin Xu, Armand Bankhead, Xiaoli Tian, Jianming Tang, Mats Ljungman, Nouri Neamati
Journal: Cancer Research (2020)

Abstract GST omega 1 (GSTO1) is an atypical GST isoform that is overexpressed in several cancers and has been implicated in drug resistance. Currently, no small-molecule drug targeting GSTO1 is under clinical development. Here we have validated GSTO1 as an impactful target in oncology. Transcriptional profiling coupled with proteomics uncovered novel pharmacodynamic markers and cellular pathways regulated by GSTO1. CRISPR/Cas9 GSTO1 knockout (KO) cell lines failed to form tumors or displayed growth delay in vivo; they also formed smaller 3D spheroids in vitro. Multiomics analysis in GSTO1 KO cells found a strong positive correlation with cell adhesion molecules and IFN response pathways and a strong negative correlation with Myc transcriptional signature. In addition, several clinically used drugs showed significant synthetic lethality with loss or inhibition of GSTO1. Transcription and protein expression of tissue factor (gene name, F3) were downregulated in response to GSTO1 KO. F3 is associated with poor patient survival and promotion of tumor progression in multiple cancers and is a known risk factor for metastasis. Transcription of F3 was regulated by IL1β, whose secretion decreased upon inhibition of GSTO1, suggesting that IL1β links GSTO1 expression and F3 transcription. In summary, our results implicate GSTO1 as a potential therapeutic target in cancer and offer new mechanistic insights into its significant role in cancer progression. Significance: These findings validate GSTO1 as a therapeutic target in cancer and implicate GSTO1 in the modulation of tumor growth, immune responses, and expression of F3.
Hepatocellular type II fibrinogen inclusions in a patient with severe COVID-19 and hepatitis
Authors: Montserrat Fraga, Darius Moradpour, Florent Artru, Elodie Romailler, Jonathan Tschopp, Antoine Schneider, Haithem Chtioui, Marguerite Neerman-Arbez, Alessandro Casini, Lorenzo Alberio, Christine Sempoux
Journal: Journal of Hepatology (2020)
Is It Time to Introduce PET/CT in Rectal Cancer Guidelines?
Authors: Anna Margherita Maffione, Giampaolo Montesi, Paola Caroli, Patrick M. Colletti, Domenico Rubello, Federica Matteucci
Journal: Clinical Nuclear Medicine (2020)

Abstract At the moment, international guidelines for rectal cancer suggest to consider 18 F-FDG PET/CT scan in a few conditions: (1) at disease presentation in case of suspected or proven metastatic synchronous adenocarcinoma with potentially curable M1 disease; (2) in the recurrence workup for serial carcinoembryonic antigen level elevation; (3) in the recurrence workup with metachronous metastases documented by CT, MRI, or biopsy; (4) in case of strong contraindication to IV contrast agent administration; and (5) to evaluate an equivocal finding on a contrast-enhanced CT or MRI. PET/CT is not indicated in the follow-up or surveillance of rectal cancer. On the other hand, an attentive evaluation of the literature shows that PET/CT may also be used in some circumstances with significant levels of diagnostic accuracy. This review article aims to emphasize differences between current international guidelines and scientific literature in the role of PET/CT in rectal cancer.
Characterisation of the types of anaemia prevalent among children and adolescents aged 1–19 years in India: a population-based study
Authors: Avina Sarna, Akash Porwal, Sowmya Ramesh, Praween K Agrawal, Rajib Acharya, Robert Johnston, Nizamuddin Khan, H P S Sachdev, K Madhavan Nair, Lakshmy Ramakrishnan, Ransi Abraham, Sila Deb, Ajay Khera, Renu Saxena
Journal: The Lancet Child & Adolescent Health (2020)
Innovative Transthoracic Echocardiographic Imaging on Prone Ventilated Patients With COVID-19 Using a Transesophageal Probe
Authors: Apostolia Marvaki, Alexandros Papachristidis, Eleni Nakou, Eva Toth, Kevin O'Gallagher, Richard Fisher, Ajay M. Shah, Mark J. Monaghan
Journal: JACC. Cardiovascular imaging (2020)
Abstract 14967: Cardiac Toxicity and Cardiovascular Events Among Adult Patients Treated With Chimeric Antigen Receptor T-Cells: A Multi-Center Registry
Authors: Raza M Alvi, Michael G Fradley, Matthew J Frigault, Michael D Jain, Syed S Mahmood, Magid Awadalla, Dae Hyun Lee, Daniel A Zlotoff, Lili Zhang, Emmanuel Bassily, Malek Z Hassan, Zsofia D Drobni, Isaac Rhea, Roohi Ismail-Khan, Connor P Mulligan, Adam Rokicki, Dahlia Banerji, Aleksandr Lazaryan, Bijal D Shah, Noopur Raje, Julio C Chavez, Jeremy Abramson, Frederick L Locke, Tomas G Neilan
Journal: Circulation (2019)

Introduction: Chimeric antigen receptors redirect T-cells (CAR-T) to target cancer cells. Recently, associations between other immunotherapies with cardiovascular (CV) events have been described. T...
Changing Causes of US Neurological Disease Mortality From 1999 to 2017
Authors: Sean N. Neifert, Ian T. McNeill, Robert J. Rothrock, John M. Caridi, J Mocco, Eric Karl Oermann
Journal: JAMA Neurology (2020)

This study estimates neurological disease mortality rate trends in the US population from 1999 to 2017 as well as regionalized differences within the US.
Telemedicine allows quantitative measuring of olfactory dysfunction in COVID‐19
Authors: Ludger Klimek, Jan Hagemann, Ali Alali, Magdalena Spielhaupter, Tilman Huppertz, Karl Hörmann, Sabine Stielow, Laura Freudelsperger, Christoph Matthias
Journal: Allergy (2020)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.